You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

AML with FLT3-ITD or FLT3-TKD and TP53wt

Showing 1 - 25 of 1,757
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

AML, Adult Trial in Berne (HDM201, Midostaurin)

Terminated
  • AML, Adult
  • Berne, Switzerland
    Departement of Medical Oncology, University Hospital Berne
Oct 3, 2022

Acute Myeloid Leukemia With FLT3/ITD Mutation Trial (XY0206, Salvage Chemotherapy)

Not yet recruiting
  • Acute Myeloid Leukemia With FLT3/ITD Mutation
  • (no location specified)
May 24, 2023

The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD

Recruiting
  • Acute Myeloid Leukemia With FLT3/ITD Mutation
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • Guangzhou, Guangdong, China
    Department of Hematology,Nanfang Hospital, Southern Medical Univ
Oct 25, 2022

The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or

Recruiting
  • Acute Myeloid Leukemia With FLT3/ITD Mutation
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • Guangzhou, Guangdong, China
    Department of Hematology,Nanfang Hospital, Southern Medical Univ
Oct 25, 2022

AML, Adult, Refractory AML, Relapsed Adult AML Trial in France (AzaCITIDine Oral Tablet, Xospata)

Not yet recruiting
  • AML, Adult
  • +4 more
  • Amiens, France
  • +19 more
Sep 1, 2023

Leukemia, Acute Myeloid (AML) Trial (Clifutinib, LoDAC, Azacitidine)

Not yet recruiting
  • Leukemia, Acute Myeloid (AML)
  • (no location specified)
Oct 16, 2022

Acute Myeloid Leukemia With FLT3/ITD Mutation Trial in Tampa (Gilteritinib, Vyxeos)

Suspended
  • Acute Myeloid Leukemia With FLT3/ITD Mutation
  • Tampa, Florida
    Moffitt Cancer Center
Nov 11, 2022

Acute Myeloid Leukemia Trial (Quizartinib, Treatment according to Physician's Choice, Standard of Care Chemotherapy)

Withdrawn
  • Acute Myeloid Leukemia
  • (no location specified)
May 18, 2022

Co-existing Mutations on Sorafenib Maintenance Therapy After

Completed
  • Acute Myeloid Leukemia
  • +2 more
  • Guangzhou, Guangdong, China
    Department of Hematology,Nanfang Hospital, Southern Medical Univ
May 30, 2022

Leukemia, Myeloid, Acute Trial in United States (CPX-351, Quizartinib)

Terminated
Has Results
  • Leukemia, Myeloid, Acute
  • Denver, Colorado
  • +4 more
May 10, 2022

Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem

Recruiting
  • Acute Myeloid Leukemia (AML)
  • Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)
  • Cincinnati, Ohio
  • +18 more
Jan 20, 2023

Acute Myeloid Leukemia Trial in United States (Quizartinib, Milademetan)

Terminated
Has Results
  • Acute Myeloid Leukemia
  • Los Angeles, California
  • +7 more
Mar 14, 2022

Leukemia, Myeloid, Acute Trial in France (Ponatinib 30 MG)

Recruiting
  • Leukemia, Myeloid, Acute
  • Ponatinib 30 MG
  • Angers, France
  • +13 more
Aug 4, 2021

Acute Myeloid Leukemia With FLT3/ITD Mutation Trial in Italy (Cytarabine, Daunorubicin, Midostaurin)

Recruiting
  • Acute Myeloid Leukemia With FLT3/ITD Mutation
  • Bari, Italy
  • +19 more
Mar 1, 2022

AML, FLT3-ITD Mutation Trial in Hong Kong (Quizartinib, Omacetaxine Mepesuccinate Injection)

Unknown status
  • AML
  • FLT3-ITD Mutation
  • Hong Kong, Hong Kong
    The University of Hong Kong
Dec 9, 2020

Acute Myeloid Leukemia Trial in Worldwide (Quizartinib, Intrathecal (IT) triple chemo prophylaxis, Fludarabine)

Recruiting
  • Acute Myeloid Leukemia
  • Loma Linda, California
  • +36 more
Feb 1, 2023

AML According to WHO 2016 Classification (Except Acute Promyelocytic Leukemia) AND (Refractory to Induction Therapy OR Relapsed

Recruiting
  • AML According to WHO 2016 Classification (Except Acute Promyelocytic Leukemia) AND (Refractory to Induction Therapy OR Relapsed After First Line Treatment)
  • MRD-triggered arm
  • Prophylactic Arm
  • Heidelberg, BW, Germany
    University Hospital Heidelberg Med5
Jan 4, 2021

FLT3-ITD Mutation, FLT3/TKD Mutation, PDGFR-Alpha D842V Trial in Genova (Crenolanib besylate)

Available
  • FLT3-ITD Mutation
  • +3 more
  • Crenolanib besylate
  • Genova, Italy
    Ospedale Policlinico San Martino
May 21, 2020

Acute Myeloid Leukemia Trial in United States (Gilteritinib, Midostaurin, Daunorubicin)

Active, not recruiting
  • Acute Myeloid Leukemia
  • Scottsdale, Arizona
  • +43 more
Nov 17, 2022

Acute Myeloid Leukemia Trial in Canada, United States (Midostaurin, Standard of Care)

Completed
Has Results
  • Acute Myeloid Leukemia
  • La Jolla, California
  • +18 more
Mar 12, 2021

FLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid

Not yet recruiting
  • Acute Myeloid Leukemia
    • (no location specified)
    May 17, 2022

    Acute Myeloid Leukemia Trial in Germany (midostaurin (PKC412))

    Completed
    • Acute Myeloid Leukemia
    • midostaurin (PKC412)
    • Chemnitz, Germany
    • +9 more
    Aug 5, 2020

    AML, FLT3-ITD Mutation Trial in Hong Kong (Sorafenib, Omacetaxine Mepesuccinate Injection)

    Completed
    • AML
    • FLT3-ITD Mutation
    • Hong Kong, Hong Kong
      The University of Hong Kong
    Mar 26, 2020

    Sorafenib to Treat FLT3-ITD AML

    Recruiting
    • Acute Myeloid Leukemia
    • FLT3-ITD Mutation
      • Suzhou, Jiangsu, China
        The First Affiliated Hospital of Soochow University
      Feb 3, 2020

      FLT3-ITD Mutation, AML Trial in Hong Kong (Sorafenib 200mg)

      Completed
      • FLT3-ITD Mutation
      • AML
      • Sorafenib 200mg
      • Hong Kong, Hong Kong
        The University of Hong Kong
      Mar 26, 2020